Literature DB >> 2307172

Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.

A J Brendel1, B Lambert, M Guyot, R Jeandot, H Dubourg, P Roger, S Wynchauk, G Manciet, G Lefort.   

Abstract

We evaluated the reliability of very low serum thyroglobulin (Tg) levels (less than 3 ng/ml) obtained after withdrawal of thyroid suppression therapy in 224 patients without anti-Tg antibodies, who had undergone total thyroidectomy (125 patients) or thyroidectomy followed by 1 or more courses of 131I therapy (99 patients), by performing whole body scans after a therapeutic course of 131I given at the same time of Tg measurement. In 79 patients (35%) a positive scan, associated with a very low level of Tg, was noted. The 131I uptake was limited to the thyroid bed in 60 patients, but metastases were demonstrated in 19 patients (8.5%). These results are mainly explained by the much improved performance of scintigraphy after administration of therapeutic doses of 131I. In the majority of patients, especially those whose 131I uptake was limited to the thyroid bed, further scans were negative. Therefore, in these cases, negative Tg values can generally be considered an early indication of satisfactory evolution. However, in 8.5% of all cases, very low Tg levels were associated with metastases. Thus the follow up of thyroid cancer should not rely only upon Tg determination, even after suppression therapy withdrawal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307172     DOI: 10.1007/bf01566010

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  20 in total

1.  Radioimmunoassay for human antithyroglobulin antibodies. I. The relationship between tanned cell haemagglutination and a double antibody technique.

Authors:  G B Salabé; S Fontana; M Andreoli
Journal:  Hormones       Date:  1972

Review 2.  Radionuclide diagnosis and therapy of thyroid cancer: current status report.

Authors:  J E Freitas; M D Gross; S Ripley; B Shapiro
Journal:  Semin Nucl Med       Date:  1985-04       Impact factor: 4.446

3.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

Review 4.  [Significance of thyroglobulin as a tumor marker in the serum of patients with differentiated thyroid carcinoma: longitudinal and cross-sectional studies (author's transl)].

Authors:  H Schatz; S Grebe; E Mäser; J Teuber; W Horn; O Schröder; C Schatz
Journal:  Klin Wochenschr       Date:  1982-05-03

5.  Correlation of thyroglobulin measurements and radioiodine scans in the follow-up of patients with differentiated thyroid cancer.

Authors:  L Ramanna; A D Waxman; M B Brachman; N Sensel; D E Tanasescu; D S Berman; B Catz; G D Braunstein
Journal:  Cancer       Date:  1985-04-01       Impact factor: 6.860

6.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

7.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.

Authors:  F Pacini; F Lippi; N Formica; R Elisei; S Anelli; C Ceccarelli; A Pinchera
Journal:  J Nucl Med       Date:  1987-12       Impact factor: 10.057

8.  Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication.

Authors:  W H Blahd; M V Drickman; C W Porter; V A Hill; W A Baumgartner
Journal:  J Nucl Med       Date:  1984-06       Impact factor: 10.057

9.  The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.

Authors:  A Waxman; L Ramanna; N Chapman; D Chapman; M Brachman; D Tanasescu; D Berman; B Catz; G Braunstein
Journal:  J Nucl Med       Date:  1981-10       Impact factor: 10.057

10.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

View more
  14 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.

Authors:  Paolo Zanotti-Fregonara; Gaia Grassetto; Elif Hindié; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02       Impact factor: 9.236

3.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

4.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01

5.  The role of ultrasound in the follow-up of children with differentiated thyroid cancer.

Authors:  Reza Vali; Marianna Rachmiel; Jill Hamilton; Mohamad El Zein; Jonathan Wasserman; Danny L Costantini; Martin Charron; Alan Daneman
Journal:  Pediatr Radiol       Date:  2014-12-19

6.  Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

Authors:  A S Alzahrani; H Raef; A Sultan; S Al Sobhi; S Ingemansson; M Ahmed; A Al Mahfouz
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

7.  Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning.

Authors:  Elisa Caballero-Calabuig; Carmen Cano-Terol; Ramón Sopena-Monforte; Dolores Reyes-Ojeda; Pedro Abreu-Sánchez; José Ferrer-Rebolleda; Pablo Sopena-Novales; Carmen Plancha-Mansanet; Jesús Félix-Fontestad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

8.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

Review 9.  Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  Is Every Patient Followed up as a Papillary Thyroid Cancer Patient Really That?

Authors:  Ummuhan Abdulrezzak; Ahmet Tutus; Mustafa Kula; Figen Oztürk; Işın Soyuer
Journal:  Mol Imaging Radionucl Ther       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.